Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief
… has orphan drug designation (ODD) in the U.S. and Europe. Partnership with Foundation Fighting Blindness (FFB) where … and planned to start in 2018 subject to a potential partnership. Eluforsen has FDA Fast Track designation and ODD …
… in preclinical models, a robust IP estate, a fruitful partnership with Eli Lilly, and cash runway into mid-2026.” … with potential additional milestone income from existing partnership, and potential option to exercise for expansion … opt-in payment to ProQR. ProQR may selectively form new partnerships, which could include multi-target discovery …
… continues to execute on its global licensing and research partnership with Eli Lilly, focused on the discovery, … and nervous system, and may selectively enter additional partnerships designed to advance and capture the full … excludes any revenue generated from the Company’s existing partnership and any potential new partnering deals. “As we …
Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 P
… In parallel, ProQR will continue to execute on its partnership with Lilly and selectively enter into additional partnerships designed to advance and capture the full … IP estate in the ADAR editing space, a first industry partnership, and with its broad applicability the platform …
Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
… our preclinical proof of concept data for the platform, a partnership with Eli Lilly, a leading IP position, and strong … and pipeline programs. Continue to execute on existing partnership with Eli Lilly and Company (Lilly). ProQR may selectively form new partnerships, which could include multi-target discovery …